Cytek Biosciences, Inc. (CTKB)

Cytek Biosciences, Inc. (CTKB) is a healthcare company (medical devices) based in the United States. The share price is $5.67, up 0.62% on the day, which values the company at $740.89M. Price as of 17 Nov 2026, 17:28 UTC, from Yahoo Finance.

Key facts

Share price
$5.67+0.62% today
Market value
$740.89M
Forward P/E
80.9×
Funk Score
48/100
Against its own history
Well below its usual priceusual price $8.93
200-week average
$5.924% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Cytek Biosciences, Inc. in more detail

CTKB trades at 80.9× next year's expected earnings, 3.6× sales. Measured against its own history, the price is 37% below what its usual multiples would imply ($8.93) — well below its usual price. It sits 4% below its 200-week average of $5.92.

Over the last five fiscal years Cytek Biosciences, Inc. has compounded revenue 16.8% a year. Its Funk Score is 48 out of 100 (financial strength 5.7, profitability 1.0, growth 7.7, value 4.8, each out of 10).

In its favour: Altman Z in the safe zone; Share count keeps falling. Worth checking: Gross margin is shrinking; Thin interest cover.

1 of the superinvestors tracked here hold CTKB, including Zhang Lei (3.5% of the portfolio).

Superinvestors holding CTKB

1 of the investors tracked here report a position in their latest 13F filing.

Cytek Biosciences, Inc. (CTKB): questions and answers

What is Cytek Biosciences, Inc.'s market cap?

Cytek Biosciences, Inc. is valued at $740.89M at a share price of $5.67.

Is CTKB overvalued or undervalued?

Against its own history, CTKB is well below its usual price: the price is 37% below the $8.93 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is CTKB above its 200-week moving average?

No. CTKB is 4.4% below its 200-week average of $5.92. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Cytek Biosciences, Inc. growing?

Over the last five fiscal years Cytek Biosciences, Inc.'s revenue grew 16.8% a year.

Does CTKB pay a dividend?

Cytek Biosciences, Inc. does not currently pay a regular dividend.

Which famous investors own CTKB?

In their latest quarterly filings, Zhang Lei (3.5% of the portfolio) hold CTKB. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Cytek Biosciences, Inc. (CTKB) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CTKB

Underlying data: Yahoo Finance; company filings with the SEC.